NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global ADME-Toxicology Testing Industry
http://www.reportlinker.com/p0611076/Global-ADME-Toxicology-Testing-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnosti
This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ Million by the following Product Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 83 companies including many key and niche players such as Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., Aureus Sciences, Bayer Technology Services GmbH, BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd., CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cerep SA, CompuDrug International, Inc., Cyprotex PLC, Entelos, Inc., Galapagos NV, Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Pharmaron, Inc., Promega Corporation, Qualyst, Inc., Simulations Plus, Inc., Sirius Analytical Instruments Ltd., Taconic Farms, Inc., Tecan Group Ltd., Thermo Fisher Scientific, Inc., and Xceleron, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
ADME-Tox - An Introduction 3
Toxicology Testing 4
ADME Testing 4
Absorption 4
Distribution 4
Metabolism 4
Excretion 5
2. INDUSTRY OVERVIEW 6
ADME-Tox Testing Gains Traction 6
Table 1: Leading Causes of Failure During New Drug
Development: Percentage Share Breakdown by ADME/Tox Issues,
Insufficient Efficacy, Adverse Side Effects, and Commercial
Viability (includes corresponding Graph/Chart) 6
Current and Future Analysis 7
Pharma Industry Renews Focus on Cost Optimization 7
Table 2: US R&D Productivity Trends in Pharma Industry (2000-
2010) (includes corresponding Graph/Chart) 8
China and India: Hot Spots for R&D Investment 8
Table 3: Percentage Breakup of Global R&D Spending by Region
(2009) (includes corresponding Graph/Chart) 9
CROs Expand Presence 9
Growing Need for Collaborations 10
3. MARKET DYNAMICS 11
Trends and Technologies Shaping the ADME/Tox Market 11
Growing Inclination Towards In-vitro Assays for Toxicology
Studies 11
Focus Shifts to Innovative Approaches 11
Increasing Use of Cell-Based Assays over Other Methods in
Toxicity Testing 11
Functional Assays: An Effective Way of Predicting Specific
Toxic Effects 12
Introduction of Early In Vitro ADMET Studies 12
Stem Cells in Drug Discovery 13
Primary Hepatocytes Become Standard Tool for Evaluation in
Hepatic Metabolism 13
3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing 13
In Silico ADME-Tox Growing at a Fast Clip 13
Factors Hindering Growth 14
Cardiotoxicity Testing Gains Prominence 14
Computational Models on Rise 14
Adoption of Data Management Systems 15
Drug Transporter Analysis Becoming Part of ADME Assessment 15
Regulatory Bodies Focus on Transporter Mediated DDIs 15
4. DRUG DISCOVERY & DEVELOPMENT 16
Table 4: Escalating Costs of New Drug Development Over the
Decades (includes corresponding Graph/Chart) 16
Drug Discovery and Development 17
Target identification 17
Target Validation 17
Lead Identification 18
Lead Optimization 18
Pre-Clinical Testing 19
Clinical Trials 19
Drug Discovery Technologies 20
Innovation in Screening Guarantees Success for Drug Discovery
Programs 20
5. PRODUCT OVERVIEW 21
ADME-Tox - An Introduction 21
Absorption 21
Distribution 21
Metabolism 21
Excretion 22
Toxicity 22
ADME-Tox Profiling 22
ADME-Tox Screening Technologies 22
ADME-Tox Parameters 23
Cell Based Assays 24
Liver Cell Based Assays 24
Intestinal Cell Based Assays 24
Kidney Cell Based Assays 24
6. PRODUCT LAUNCHES/INNOVATIONS/ REGULATORY APPROVALS 25
Simulations Plus to Develop Predictive QSAR Toxicity Models in
Partnership with FDA 25
BIOCIUS Life Sciences Extends Contract Research Services
Range, Introduces New ADME Assay Analysis 25
LGC Unveils reinnervate's 3D Cell Culture Scaffold, Alvetex®
for In Vitro Toxicity Testing for Drug Discovery 25
Cyprotex Unveils Cyprotox®, In Vitro Toxicology Services 25
Absorption System Rolls Out Express Plus ADME Assays 26
LGC Standards Unveils ADME Toxicology Guide for New Drug
Discovery 26
Absorption System Secures Patent for BCP Knockdown Cell Line
in CellPort Technologies Brand 26
Cyprotex Relaunches CellCiphr™ Toxicity Panels 26
Sigma® Life Science Launches New Models of Knockout Rats for
ADME-Tox Applications 27
Hudson Robotics Unveils VaryScreen ADME-Tox Workstation 27
Agilent Technologies Rolls Out RF360 High Resolution System
for High-Throughput Screening of In Vitro ADME Assays 27
MultiCell Technologies Receives Patent for EA1C-35 and Fa2N-4
Immortalized Human Hepatocyte Cell Lines 28
Cyprotex Unveils Web Portal for Providing Access to Drug
Discovery Services 28
Applied Biosystems/MDS Analytical Technologies Launches
DiscoveryQuant™ Software 28
BioTrove Releases RapidFire 300 System for High-Throughput
Screening 28
CXR Biosciences and Millipore Launch ToxReporter™ 29
7. RECENT INDUSTRY ACTIVITY 30
CIT and Stemina Ink Strategic Partnership Deal for
Distribution of Toxicity Assay and New Technology Development 30
Hamner forms Research Initiative for Development of 3D Tissue
Bioassays for Toxicity Testing 30
Aureus Pharma Becomes Aureus Sciences and Unveils Extensive
Life Sciences Application Web Portal 30
CeeTox Purchases ADMETRx's Assets 30
Phytopharm to Receive Chemistry and ADME Services Support from
O2h 31
Life Technologies Inks Licensing Agreement with Biopredic
International for HepaRG® Cells 31
O2h to Provide ADME Services to Sentinel Oncology 31
Galapagos Takes Over Argenta Discovery, Becomes Leading Drug
Discovery Services Provider 31
BioFocus to Offer ADME Services as Part of Extended
Partnership Deal with Chisei 31
Cyprotex to Take Over Apredica and Cellumen 32
Optivia and UCSF Receive SBIR Grant for Development of ADME
Systems 32
Accelrys Merges with Symyx 32
Lonza Group Purchases Simbiosys Biowares India Pvt Ltd 33
Gentronix and Apredica Collaborate for Predictive Toxicology
Services 33
AsisChem Joins Forces with Apredica for Drug Discovery Support
Services 33
Batelle Ventures Funds Hepregen's Spin-Off from MIT 34
ADMETRx and CeeTox Enter into Partnership to Provide Extensive
ADME-Tox Services 34
Promega and Celsis IVT Ink Agreement to Collaborate for ADME-
Tox Testing in Primary Hepatocytes 34
Pharma Algorithms and ACD/Labs Collaborate to Enhance In
Silico Prediction and Screening 35
8. FOCUS ON SELECT GLOBAL PLAYERS 36
Accelrys, Inc. (US) 36
ACEA Biosciences, Inc. (US) 36
Agilent Technologies, Inc. (US) 36
Albany Molecular Research, Inc. (US) 37
Aureus Sciences (France) 37
Bayer Technology Services GmbH (Germany) 37
BD Biosciences (US) 38
Beckman Coulter, Inc. (US) 38
Bio-Rad Laboratories, Inc. (US) 38
Caliper Life Sciences, Inc. (US) 39
Cambridge Cell Networks Ltd. (UK) 39
CeeTox, Inc. (US) 39
Cellartis AB (Sweden) 40
Celsis International Ltd. (US) 40
Cerep SA (France) 40
CompuDrug International, Inc. (US) 40
Cyprotex PLC. (US) 41
Entelos, Inc. (US) 41
Galapagos NV (Belgium) 41
Life Technologies Corporation (US) 41
Molecular Discovery Ltd (UK) 42
MultiCASE, Inc. (US) 42
Noray Bioinformatics S.L. (Spain) 42
Optivia Biotechnology 42
Pharmaron, Inc. (US) 43
Promega Corporation (US) 43
Qualyst, Inc. (US) 43
Simulations Plus, Inc. (US) 43
Sirius Analytical Instruments Ltd (UK) 44
Taconic Farms, Inc. (US) 44
Tecan Group Ltd. (Switzerland) 44
Thermo Fisher Scientific, Inc. (US) 44
Xceleron, Inc. (UK) 45
9. GLOBAL MARKET PERSPECTIVE 46
Table 5: World Recent Past, Current & Future Analysis for ADME-
Tox Testing by Geographic Region - US, Canada, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2008 Through
2017 (includes corresponding Graph/Chart) 46
Table 6: World 10-Year Perspective for ADME - Tox Testing by
Geographic Region - Percentage Breakdown of Dollar Revenues
for US, Canada, Japan, Europe, and Rest of World Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/
Chart) 47
Table 7: World Recent Past, Current & Future Analysis for
Toxicology Testing by Geographic Region - US, Canada, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2008 Through
2017 (includes corresponding Graph/Chart) 48
Table 8: World 10-Year Perspective for Toxicology Testing by
Geographic Region - Percentage Breakdown of Dollar Revenues
for US, Canada, Japan, Europe, and Rest of World Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 49
Table 9: World Recent Past, Current & Future Analysis for
Toxicology Testing by Sub-Segment - In-Vivo and In-Vitro
Testing Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2008 Through 2017 (includes
corresponding Graph/Chart) 50
Table 10: World 10-Year Perspective for Toxicology Testing by
Sub-Segment - Percentage Breakdown of Dollar Revenues for
In-Vivo and In-Vitro Testing Markets for Years 2008, 2011 &
2017 (includes corresponding Graph/Chart) 50
Table 11: World Recent Past, Current & Future Analysis for
In-Vivo Toxicology Testing by Geographic Region - US, Canada,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart) 51
Table 12: World 10-Year Perspective for In-Vivo Toxicology
Testing by Geographic Region - Percentage Breakdown of Dollar
Revenues for US, Canada, Japan, Europe, and Rest of World
Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) 52
Table 13: World Recent Past, Current & Future Analysis for
In-Vitro Toxicology Testing by Geographic Region - US, Canada,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2008 Through 2017 (includes corresponding Graph/Chart) 53
Table 14: World 10-Year Perspective for In-Vitro Toxicology
Testing by Geographic Region - Percentage Breakdown of Dollar
Revenues for US, Canada, Japan, Europe, and Rest of World
Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) 54
Table 15: World Recent Past, Current & Future Analysis for
ADME Testing by Geographic Region - US, Canada, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 55
Table 16: World 10-Year Perspective for ADME Testing by
Geographic Region - Percentage Breakdown of Dollar Revenues
for US, Canada, Japan, Europe, and Rest of World Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 56
10. THE UNITED STATES 57
A.Market Analysis 57
Current and Future Analysis 57
Clinical Trials Market in the US 57
Product Launches/Regulatory Approvals 57
Strategic Corporate Developments 60
Select Players 63
B.Market Analytics 71
Table 17: US Recent Past, Current & Future Analysis for ADME-
Tox Testing by Segment - Toxicology (In-Vivo and In-Vitro)
and ADME Markets Independently Analyzed with Annual Revenues
in US$ Million for Years 2008 Through 2017 (includes
corresponding Graph/Chart) 71
Table 18: US 10-Year Perspective for ADME - Tox Testing by
Segment - Percentage Breakdown of Dollar Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years
2008, 2011 & 2017 (includes corresponding Graph/Chart) 72
11. CANADA 73
A.Market Analysis 73
Strategic Corporate Development 73
B.Market Analytics 74
Table 19: Canadian Recent Past, Current & Future Analysis
for ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 74
Table 20: Canadian 10-Year Perspective for ADME - Tox
Testing by Segment - Percentage Breakdown of Dollar Revenues
for Toxicology (In-Vivo and In-Vitro) and ADME Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 75
12. JAPAN 76
Market Analysis 76
Table 21: Japanese Recent Past, Current & Future Analysis
for ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 76
Table 22: Japanese 10-Year Perspective for ADME - Tox
Testing by Segment - Percentage Breakdown of Dollar Revenues
for Toxicology (In-Vivo and In-Vitro) and ADME Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 77
13. EUROPE 78
A.Market Analysis 78
Current and Future Analysis 78
Clinical Trials Market in Europe 78
Product Launches/Regulatory Approvals 78
Strategic Corporate Developments 79
Select Players 81
B.Market Analytics 84
Table 23: European Past, Current & Future Market Analysis
for ADME - Tox Testing by Country/Geographic Region -
France, Germany, Italy, UK, and Rest of Europe Markets
Independently Analyzed with Annual Revenues in US$ Million
for Years 2008 through 2017 (includes corresponding
Graph/Chart) 84
Table 24: European Recent Past, Current & Future Analysis
for ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 85
Table 25: European 10-Year Perspective for ADME - Tox
Testing by Country/Geographic Region - Percentage Breakdown
of Dollar Sales for France, Germany, Italy, UK, and Rest of
Europe Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart) 86
Table 26: European 10-Year Perspective for ADME - Tox
Testing by Segment - Percentage Breakdown of Dollar Revenues
for Toxicology (In-Vivo and In-Vitro) and ADME Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 87
13a. FRANCE 88
Market Analysis 88
Table 27: France Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 88
Table 28: French 10-Year Perspective for ADME - Tox Testing
by Segment - Percentage Breakdown of Dollar Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years
2008, 2011 & 2017 (includes corresponding Graph/Chart) 89
13b. GERMANY 90
Market Analysis 90
Table 29: German Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
includes corresponding Graph/Chart) 90
Table 30: German 10-Year Perspective for ADME - Tox Testing
by Segment - Percentage Breakdown of Dollar Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years
2008, 2011 & 2017 (includes corresponding Graph/Chart) 91
13c. ITALY 92
Market Analysis 92
Table 31: Italian Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 92
Table 32: Italian 10-Year Perspective for ADME - Tox Testing
by Segment - Percentage Breakdown of Dollar Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years
2008, 2011 & 2017 (includes corresponding Graph/Chart) 93
13d. THE UNITED KINGDOM 94
Market Analysis 94
Table 33: The UK Recent Past, Current & Future Analysis for
ADME - Tox Testing by Segment - Toxicology (In-Vivo and
In-Vitro) and ADME Markets Independently Analyzed with
Annual Revenues in US$ Million for Years 2008 Through 2017
(includes corresponding Graph/Chart) 94
Table 34: The UK 10-Year Perspective for ADME - Tox Testing
by Segment - Percentage Breakdown of Dollar Revenues for
Toxicology (In-Vivo and In-Vitro) and ADME Markets for Years
2008, 2011 & 2017 (includes corresponding Graph/Chart) 95
13e. REST OF EUROPE 96
A.Market Analysis 96
Russia 96
Table 35: Russian Clinical Trials Market (2009): Percentage
Breakdown by Trial Type - Global Multi- center Clinical
Trials, Local Clinical Trials (Foreign Sponsors), Local
Clinical Trials (Local Sponsors), Bioequivalence studies
(Foreign Sponsors), and Bioequivalence Studies (includes
corresponding Graph/Chart) 96
Table 36: Russian Clinical Trials Market (2008): Percentage
Breakdown by Hosting Countries - Russia, USA, Germany, UK,
Switzerland, and Others (includes corresponding
Graph/Chart) 97
Table 37: Number of Clinical Trials in Russia by Study
Phase (2008) (includes corresponding Graph/Chart) 97
Spain 97
Garnering Investments from Multinational Pharma Companies 97
Phase III Clinical Trials Engross Maximum R&D Expenditure 97
Table 38: Apportion of R & D Expenditure by Study Phase in
Spain: 2008 (includes corresponding Graph/Chart) 98
B.Market Analytics 98
Table 39: Rest of Europe Recent Past, Current & Future
Analysis for ADME - Tox Testing by Segment - Toxicology
(In-Vivo and In-Vitro) and ADME Markets Independently
Analyzed with Annual Revenues in US$ Million for Years 2008
Through 2017 (includes corresponding Graph/Chart) 98
Table 40: Rest of Europe 10-Year Perspective for ADME - Tox
Testing by Segment - Percentage Breakdown of Dollar Revenues
for Toxicology (In-Vivo and In-Vitro) and ADME Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 99
14. REST OF WORLD 100
A.Market Analysis 100
Current and Future Analysis 100
Asia: The Most Preferred Destination for Clinical Trials 100
India 100
A Thriving Clinical Trials Market 100
Table 41: Cost of Conducting Clinical Trials: India Vs.
US (In US$ Million) (includes corresponding Graph/Chart) 101
Latin America: An Emerging Market for Clinical Trials 101
Table 42: Latin American Clinical Trials Market by Country
(2009): Percentage Share Breakdown for Brazil, Mexico,
Argentina, Chile, Peru, Colombia, Costa Rica, Guatemala,
and Panama (includes corresponding Graph/Chart) 102
Strategic Corporate Development 102
B.Market Analytics 103
Table 43: Rest of World Recent Past, Current & Future
Analysis for ADME - Tox Testing by Segment - Toxicology
(In-Vivo and In-Vitro) and ADME Markets Independently
Analyzed with Annual Revenues in US$ Million for Years 2008
Through 2017 (includes corresponding Graph/Chart) 103
Table 44: Rest of World 10-Year Perspective for ADME - Tox
Testing by Segment - Percentage Breakdown of Dollar Revenues
for Toxicology (In-Vivo and In-Vitro) and ADME Markets for
Years 2008, 2011 & 2017 (includes corresponding Graph/Chart) 104
COMPETITIVE LANDSCAPE
Total Companies Profiled: 83 (including Divisions/Subsidiaries - 87)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 53
Canada 2
Japan 1
Europe 21
France 4
Germany 4
The United Kingdom 13
Spain 3
Rest of Europe 6
Asia-Pacific (Excluding Japan) 1
------------------------------------------
To order this report:
Diagnostics Industry: Global ADME-Toxicology Testing Industry
Diagnostics Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article